✦ LIBER ✦

The relationship between immunologic response and recurrence in a phase II trial evaluating the HER-2/neu peptide vaccines AE37 and GP2 in breast cancer patients in the adjuvant setting

✍ Scribed by Alan K. Sears; Guy T. Clifton; Linda C. Benavides; Jeremy D. Gates; Jarrod P. Holmes; Sonia Perez; Sathibalan Ponniah; Michael Papamichail; George E. Peoples; Elizabeth A. Mittendorf

Book ID: 113680839
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 97 KB
Volume: 213
Category: Article
ISSN: 1072-7515
DOI: 10.1016/j.jamcollsurg.2011.06.335

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical and Immunologic Responses of HL

Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/neu-Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial

✍ Ritesh Patil; Guy T. Clifton; Jarrod P. Holmes; Asna Amin; Mark G. Carmichael; J 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 728 KB

Immunological monitoring of in vitro and

Immunological monitoring of in vitro and in vivo immune responses to the Ii-Key/HER2/neu MHC class II peptide vaccine in a phase I clinical trial in breast cancer patients

✍ S. Khoo; C.E. Storrer; K.A. Harris; Y.H. Jama; Z.A. Dehqanzada; C.D. Shriver; E. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB

A phase I trial evaluating the safety an

A phase I trial evaluating the safety and immunogenicity of a HER-2 protein vaccine in patients with breast cancer

✍ B Overmoyer; A Brufsky; B Volck; D Leach; A Oestergaard 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 174 KB

A more sensitive immunological monitorin

A more sensitive immunological monitoring tool for cancer vaccine trials: A direct comparison of HLA-A2 dimer and tetramer molecules in measuring the in vivo immune response to a HER2/neu peptide-based vaccine (E75) in prostate and breast cancer patients

✍ Matthew T. Hueman; Jennifer Gurney; Michael Woll; Catherine Storrer; David McLeo 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Results of the first phase 1 clinical tr

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients : United States Military Cancer Institute Clinical Trials Group Study I-04

✍ Mark G. Carmichael; Linda C. Benavides; Jarrod P. Holmes; Jeremy D. Gates; Eliza 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 1 views

Final results of a multicenter phase II

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

✍ Marta Pestrin, Silvia Bessi, Fabio Puglisi, Alessandro M. Minisini, Giovanna Mas 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 246 KB